The Blood Brain Barrier (BBB)
Medicinal chemistry is both science and art. The science of medicinal chemistry offers mankind one of its best hopes for improving the quality of life. The art of medicinal chemistry continues to challenge its practitioners with the need for both intuition and experience to discover new drugs. Hence...
Saved in:
| Other Authors: | , , |
|---|---|
| Format: | Edited Volume |
| Language: | English |
| Published: |
Berlin, Heidelberg
Springer
2014
|
| Series: | Topics in Medicinal Chemistry
10 SpringerLink Bücher |
| DOI: | 10.1007/978-3-662-43787-2 |
| Subjects: | |
| Online Access: | Verlag, Volltext: https://doi.org/10.1007/978-3-662-43787-2 Resolving-System, lizenzpflichtig, Volltext: http://dx.doi.org/10.1007/978-3-662-43787-2 Cover: https://swbplus.bsz-bw.de/bsz417090854cov.jpg 
|
| Author Notes: | edited by Gert Fricker, Melanie Ott, Anne Mahringer |
Table of Contents:
- Preface; Contents; The Blood-Brain Barrier: An Introduction to Its Structure and Function; 1 The BBB: A Historical Perspective; 2 Evolutionary Development of a BBB; 3 Anatomic Principles of the BBB; 4 Pericytes; 5 Astrocyte: Endothelium Interactions; 6 Neurons; 7 Basal Membrane; 8 Junctional Complexes at the BBB; 9 Transport Proteins at the BBB; 10 Cytotic Processes at the BBB; 11 Outlook; References; In Vivo Approaches to Assessing the Blood-Brain Barrier; 1 Introduction; 2 Pharmacokinetic Principles of Blood-Brain Barrier Transport; 3 Methods
- 3.1 Brain Uptake Index (Carotid Artery Single Injection Technique)3.2 The i.v. Injection Technique; 3.3 In Situ Brain Perfusion; 3.4 Brain Efflux Index; 3.5 Percentage of the Injected Dose; 3.6 Microdialysis; 3.7 CSF Sampling; 3.8 Positron Emission Tomography; 3.9 Combinatorial Mapping of Kp,uu,brain; 4 Conclusions; References; ABC Transporters at the Blood-Brain Barrier; 1 Introduction; 2 ABC Transporters at the Blood-Brain Barrier; 2.1 Assessing ABC Transporter Activity/Expression; 3 Modulation of ABC Transporter Expression and Activity; 3.1 Altered Transporter Expression
- 3.1.1 Response to Xenobiotics3.1.2 Response to Disease; 3.2 Altered Transporter Activity Through Signaling; 3.2.1 Regulation of P-Glycoprotein Activity Through Sphingolipid Signaling; 3.2.2 Regulation of P-Glycoprotein Activity Through VEGF Signaling; 3.2.3 Regulation of BCRP Activity Through Estrogen Signaling; 3.2.4 Mechanisms Underlying Decreased Transporter Activity; 4 Perspectives; References; Nanoparticles as Blood-Brain Barrier Permeable CNS Targeted Drug Delivery Systems; 1 Introduction; 1.1 Blood-Brain Barrier; 1.2 Blood-Cerebrospinal Fluid Barrier (BCB) and CSF-Brain Barrier
- 1.3 CNS Drug Delivery Strategies1.4 Nanomedicine Exploitation; 1.5 Nanomedicines for BBB Crossing: General Considerations; 2 BBB Crossing Nanocarriers; 2.1 Poly(n-butylcyanoacrylate) (PBCA) NPs; 2.2 Methoxypoly(ethylene glycol)-polylactide or Poly(lactide-co-glycolide) (mPEG-PLA/PLGA) NPs; 2.3 Liposomes; 2.4 Inorganic Nanosystems; 3 Conclusions; References; Blood-Brain Barrier and Stroke; 1 Introduction; 2 Injury to BBB Cell Components After Stroke; 2.1 Endothelial Cells; 2.2 Pericytes; 2.3 Astrocytes; 3 Basement Membrane, Extracellular Matrix, and Stroke
- 4 Systemic and Local Inflammation and BBB Permeability After Stroke4.1 Chemokines, Adhesion Molecules, and Leukocyte Trafficking; 4.2 Parenchymal Brain Cells; 4.3 Perivascular Inflammatory Cells; 5 Post-ischemic Vascular and Brain Repair; 6 BBB Responses to Stroke in the Perinatal Period; 7 BBB Integrity, Angiogenesis, and Brain Repair After Stroke During the Perinatal Period; 8 Concluding Remarks; References; Inflammation at the Blood-Brain Barrier in Multiple Sclerosis; 1 Multiple Sclerosis and the Blood-Brain Barrier; 1.1 Clinical Features and Diagnosis of Multiple Sclerosis; 1.2 Etiology
- 1.3 Pathogenesis